Preeclampsia is a pregnancy-specific disorder, affecting 5% to 10% of all pregnancies, and is a significant contributor to maternal and perinatal mortality rates. Characterized by high blood pressure and proteinuria, it can lead to severe complications such as organ dysfunction, restricted fetal growth, and premature birth.

Homocysteine (HCY) and Its Link to Preeclampsia

Homocysteine, a sulfur-containing amino acid, is metabolized with the help of folate, vitamin B12, and the enzyme 5,10-methylenetetrahydrofolate reductase (MTHFR). Elevated plasma HCY levels suggest a disruption in this metabolic pathway and are correlated with an increased risk of preeclampsia. High HCY levels may precipitate preeclampsia by damaging vascular endothelium, promoting blood clot formation, and triggering oxidative stress.

5-Methyltetrahydrofolate: A Key Player in HCY Metabolism and Preeclampsia Prevention

As the active form of folate, 5-MTHF plays a pivotal role in HCY metabolism. It donates a methyl group to convert HCY back into methionine, thus reducing HCY levels in the bloodstream.

Supplementing with 5-MTHF can enhance folate metabolism, decrease HCY levels, and consequently mitigate the risk of preeclampsia. The protective effect of 5-MTHF is likely due to its ability to improve endothelial function and reduce vascular inflammation.

An Italian study demonstrated the efficacy of 5-MTHF supplementation in preventing recurrent preeclampsia in women with a history of the condition. The study involved 303 women with a history of preeclampsia, divided into two groups: one receiving 15 mg of 5-MTHF daily from early pregnancy, and the other serving as a control group without supplementation.

The findings revealed that women supplemented with 5-MTHF had a significantly lower incidence of recurrent preeclampsia (21.7% compared to 39.7% in the control group). Additionally, the rates of severe and early-onset preeclampsia were substantially reduced.

Conclusion

In conclusion, 5-MTHF supplementation may be a promising strategy for preeclampsia prevention, particularly for women with a history of the disease. By lowering HCY levels, it supports vascular health and reduces the likelihood of preeclampsia.

Among various 5-MTHF options, naturalization folate stands out for its safety. The production process is free from harmful substances like formaldehyde and p-toluenesulfonic acid, and the levels of potential impurities such as JK12A and 5-methyltetrahydrofolate are kept extremely low through patented technology, ensuring virtually non-toxic consumption. This ensures the health benefits of folate without any safety concerns.

Reference：

1.Zhang, C., Hu, J., Wang, X., & Gu, H. (2022). High level of homocysteine is associated with pre-eclampsia risk in pregnant woman: A meta-analysis. Gynecological Endocrinology, 38(9), 705-712. https://doi.org/10.1080/09513590.2022.2110233.

2.Saccone G, Sarno L, Roman A, Donadono V, Maruotti GM, Martinelli P. 5-Methyl-tetrahydrofolate in prevention of recurrent preeclampsia. J Matern Fetal Neonatal Med. 2015; published online ahead of print. DOI: 10.3109/14767058.2015.1023189.